Results 61 to 70 of about 5,080 (193)

Therapeutic Potential of Oxiracetam in Neurocognitive Disorders: A Narrative Review

Brain and Behavior, Volume 16, Issue 9, September 2026.
ABSTRACT Purpose: Cognitive impairment is a growing global health concern associated with aging, neurodegenerative diseases, stroke, and traumatic brain injury. Existing pharmacological treatments, including cholinesterase inhibitors and memantine, provide limited and variable benefits.
Hafsa Ali, Syeda Maliha, Sundas Ishtiaq, Omer Al‐Karawi, Mohammed Hammad Jaber Amin   +4 more
wiley   +1 more source

Predictors of Alzheimer's disease treatment optimism among a nationally representative sample of US older adults

Alzheimer's &Dementia: Behavior &Socioeconomics of Aging, Volume 2, Issue 3, September 2026.
Abstract INTRODUCTION Treatment optimism—the belief that treatment efficacy will significantly improve over time—has been shown to influence help‐seeking for various diseases. Little is known, however, about treatment optimism in Alzheimer's disease (AD). METHODS The National Poll on Healthy Aging surveyed a nationally representative sample of US older
Sarah McCain, Jonathan M. Reader, J. Scott Roberts   +2 more
wiley   +1 more source

EFFECTIVENESS OF LECANEMAB AND DONANEMAB TREATMENT FOR EARLY ALZHEIMER’S DISEASE [PDF]

Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by amyloid-beta (Aβ) plaques, tau neurofibrillary tangles, and other pathological factors like neuroinflammation and oxidative stress.
Bartłomiej Siuzdak, Justyna Moszkowicz, Marta Jutrzenka, Karolina Pasierb, Karol Poplicha, Patrycja Kardasz, Martyna Grodzińska, Aleksandra Piech, Maria Ufniarska, Piotr Sobkiewicz, Tomasz Ufniarski, Patrycja Ucieklak   +11 more
core   +1 more source

Mild Cognitive Impairment Diagnosis and Care Algorithms and the Role of Digital Interventions: Expert Consensus

CNS Neuroscience &Therapeutics, Volume 32, Issue 9, September 2026.
Mild cognitive impairment (MCI) carries a risk of further cognitive decline; thus, early diagnosis and intervention are important. The ASCEND Expert Group presents novel algorithms for (1) cognitive assessment/clinical diagnosis and (2) MCI management, emphasizing a multimodal strategy encompassing metabolic/cerebrovascular risk reduction, sensory loss
Nagaendran Kandiah, Yee Fai Chan, Darwin Dasig, Jacqueline Dominguez, Kar Chai Koh, Si Ching Lim, Paulus Anam Ong, Encarnita Raya‐Ampil, Raymond Chee Seong Seet, Vorapun Senanarong, Kit Mun Tan, Maw Pin Tan, Trần Công Thắng, Tong Mai Trang, Yuda Turana, Cuibai Wei, Ralf Ihl   +16 more
wiley   +1 more source

Table_1_Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials.DOCX

, 2023
ObjectiveWe performed a systematic review and meta-analysis of the cognitive effectiveness and safety of lecanemab on subjects with Alzheimer's disease (AD).MethodsWe screened the literature published before February 2023 in PubMed, Embase, Web of ...
Yuewei Chi (15415142), Ying Ma (123771), Yue Qiao (4708423), Qingyuan Zhang (435205), Qingyuan Zhang, Yue Qiao, Yuewei Chi, Ying Ma   +7 more
core   +1 more source

Dementia Risk After Glaucoma Surgery and Medical Therapy: A Multicentre Real‐World Cohort Study

International Journal of Geriatric Psychiatry, Volume 41, Issue 9, September 2026.
ABSTRACT Background and Purpose Glaucoma, a neurodegenerative optic neuropathy and leading cause of irreversible vision loss, shares vascular and neurodegenerative mechanisms with dementia. The 2024 Lancet Commission newly identified visual impairment as a modifiable dementia risk factor.
Lee‐Yuan Lin, Jie‐Syuan Wu, Wei‐Jung Jeng, Chen‐Hsin Tsai, Shu‐Yu Liu, Tsai‐Wei Huang, Fara Silvia Yuliani, Shyh‐Hsiang Lin   +7 more
wiley   +1 more source

Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer's disease: real-world data from an Austrian psychiatric memory clinic population

BJPsych Open
Background Pharmacological treatment options for patients with dementia owing to Alzheimer's disease are limited to symptomatic therapy. Recently, the US Food and Drug Administration approved the monoclonal antibody lecanemab for the treatment of amyloid-
Michaela Defrancesco, Elke R. Gizewski, Stephanie Mangesius, Malik Galijasevic, Irene Virgolini, Alexander Kroiss, Josef Marksteiner, Juliane Jehle, Burak Doganyigit, Alex Hofer   +9 more
doaj   +1 more source

Advancing Alzheimer’s care: a novel therapy with lecanemab

, 2023
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects the patient’s quality of life. The current regime of drugs only halts the symptoms of the disease, and the underlying pathology remains untouched; thus, there is ...
Priti Dhande, Advait Teli
core   +1 more source

Real-world safety profile of lecanemab: A disproportionality analysis of adverse events in the FDA adverse event reporting systemKey Points

JAPhA Pharmacotherapy
Background: Lecanemab, an antiamyloid monoclonal antibody, has emerged as a treatment option for Alzheimer disease. However, there is a pressing need for real-world evidence to inform clinical practice, particularly regarding its safety profile ...
Jayoung Han, Yuan Fang, Nicole Campbell
doaj   +1 more source

Neurocardiology: Brain–Heart Interactions in the Heart

MedComm, Volume 7, Issue 9, September 2026.
The heart and brain maintain systemic homeostasis through bidirectional communication involving neural, biochemical, and mechanical pathways. Dysregulation of these pathways contributes to a spectrum of conditions involving heart–brain interactions, including Takotsubo syndrome, the epileptic heart, stroke–heart syndrome, heart failure, cardiac ...
Wentao Wang, Hao Jia, Han Han, Jiangping Song   +3 more
wiley   +1 more source